OBJECTIVE: To investigate the effectiveness and reliability of posterior sub-Tenon @entity2995 (PSTA) application in branch @entity2994 (BRVO)-related macular @entity4 . METHODS: @entity1 with confirmed BRVO-related macular @entity4 were enrolled in the study. @entity1 were injected with a single, therapeutic dose of 40   mg PSTA. Detailed ophthalmic examination was performed at baseline and at 1, 3 and 6 months after the treatment. Best corrected visual acuity (BCVA), intraocular pressure (IOP), cataractogenic change (CC) and macular optical coherence tomography (OCT) analysis results were evaluated. The results were compared statistically. RESULTS: Forty-one eyes of 41 @entity1 with a mean age of 63.49        10.99 (55-86) years, 15 (36.6%) females, were included in the study. BCVA in LogMAR values at 1 and 3 months were significantly better than at baseline, while no significant difference from baseline was observed in sixth month values (p   <   0.001, p   <   0.001 and p   =   0.846, respectively). Central macular thickness values obtained using OCT were significantly lower at the first, third and sixth months compared to baseline (p   <   0.001 for all). IOP elevation was determined in only two eyes (4.8%) at the end of the study period, and no CC was detected in any case. CONCLUSION: PSTA application is an effective and safe option in BRVO-related macular @entity4 .

The effectiveness and reliability of posterior sub-Tenon XXXX injection in branch @entity2994 -related macular @entity4 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity2994 :: ('MESH:D012170', 'Disease') :: ['retinal vein occlusion'] @entity2995 :: ('MESH:D014222', 'Chemical') :: ['triamcinolone acetonide'] @entity4 :: ('MESH:D004487', 'Disease') :: ['edema']
@entity2995 :: (MESH:D014222,Chemical) :: ['triamcinolone acetonide']
